(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
1 May 2014 (01.05.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/064028 A1

(51) International Patent Classification:
A61K 9/00 (2006.01) *A61K 31/519* (2006.01)
A61K 31/00 (2006.01) *A61P 25/00* (2006.01)
A61K 31/444 (2006.01) *A61P 25/28* (2006.01)

(21) International Application Number:
PCT/EP2013/071921

(22) International Filing Date:
21 October 2013 (21.10.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
12189553.6 23 October 2012 (23.10.2012) EP

(71) Applicant *(for all designated States except US)*: **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, CH-4070 Basel (CH).

(71) Applicant *(for US only)*: **HOFFMANN-LA ROCHE INC.** [US/US]; 340 Kingsland Street, Nutley, New Jersey 07110 (US).

(72) Inventors: **GATTI MCARTHUR, Silvia**; Ramsteinerstrasse 28, CH-4052 Basel (CH). **SAXE, Michael**; Rebgasse 53, CH-4058 Basel (CH). **WICHMANN, Juergen**; Birkenweg 25, 79585 Steinen (DE). **WOLTERING, Thomas**; Jaegerhaeusleweg 57, 79104 Freiburg (DE).

(74) Agent: **MUELLER-AFRAZ, Simona**; Grenzacherstrasse 124, CH-4070 Basel (CH).

[Continued on next page]

(54) Title: MGLU2/3 ANTAGONISTS FOR THE TREATMENT OF AUTISTIC DISORDERS

Figure 4-a




Figure 4-d




Figure 4-b




Figure 4-e





Figure 4-c



[Continued on next page]

WO 2014/064028 A1

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

(57) **Abstract**: This invention relates to a new medical use for certain chemical compounds and pharmaceutical compositions containing them. The invention relates to compounds which are mGlu2/3 negative allosteric modulators for use in the treatment of ASD, in particular autism. In another aspect, the invention relates to a pharmaceutical composition for use in the treatment of ASD comprising a compound according to the invention and a pharmaceutically acceptable carrier.